Cryofocus

Cryofocus Medtech (Shanghai) Co., Ltd. (formerly Cryofocus Medtech (Shanghai) Co., Ltd.) was established in 2013 as a leading cryotherapy technology platform company with unique advantages in the field of minimally invasive interventional cryotherapy. Leveraging its proprietary liquid nitrogen cryoablation technology, the company is committed to building a comprehensive product portfolio primarily focused on two therapeutic areas: (i) vascular intervention for treating major cardiovascular diseases such as atrial fibrillation and hypertension, and (ii) natural orifice intervention for treating respiratory, urological, and digestive system diseases such as COPD, asthma, airway stenosis, bladder cancer, stomach cancer, and esophageal cancer.The core team members possess over a decade of experience in the research and development of medical device-related products and practical engineering applications, specializing in cryoablation technology. They have successfully developed more than 10 internationally/domestically pioneering cryoablation products, obtained 105 patents, and have 43 additional patents pending. The company has successfully developed multiple domestically leading or internationally pioneering cryoablation products, aiming to bring advanced cryoablation technology to benefit a wide range of patients.